Vision restoration therapies such as stem cell therapy,
1,2 gene therapy,
3–5 and other approaches,
6 including visual prostheses,
7–9 are currently being developed in research laboratories around the world. Among these promising possibilities, the Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc., Sylmar, CA) was the first vision restoration treatment to become commercially available, receiving the European conformity mark in 2011 and Food and Drug Administration (FDA) approval for humanitarian use in the United States in 2013.
10 In practice, the level of vision achieved by these novel approaches is often reported as hand motions or worse and restricted to rudimentary form or shape perception.
11,12 When optotype visual acuity cannot be measured, clinicians customarily describe vision in terms of the patient's ability to see hand motions, light projection, light perception, or no light perception, but these classifications do not correspond to standardized measures. In ongoing clinical trials such as the Argus II feasibility study (ClinicalTrials.gov: NCT00407602), visual function has been assessed through ad-hoc measures,
7,13,14 because standardized visual function measures proved unable to quantify the visual outcome. These ad-hoc measures include minimal angle of resolution with high contrast gratings, square localization, direction of motion perception, and light sensitivity.
13,15,16 Importantly, these measures of visual function do not capture functional vision,
17 that is, the ability to use vision in activities of daily living (ADLs),
18 and are uninformative regarding vision-related quality of life (VRQoL) of the individual.
19 Moreover, even for individuals with mild and moderate low vision
20–22 or with vision loss due to aging,
23–25 it has been shown that objective measures of vision do not correlate well with activities of daily living or psychological well-being. Therefore, to supplement the limited measures of visual function, there has been an increasing demand for patient-reported outcomes (PROs) that capture functional vision and VRQoL, especially in populations with severe vision loss.
26–30